Abstract Library

#4227 Evaluation of circulating extracellular vesicles as suitable prognostic markers in MEN1-associated non-functioning pancreatic neuroendocrine neoplasia

Introduction: Non-functioning pancreatic neuroendocrine neoplasias (NF-pNENs) significantly contribute to premature death of multiple endocrine neoplasia type 1 (MEN1) patients. Reliable prognostic markers for disease progression are lacking. Circulating liquid biomarkers, including microRNAs and Long-non-Coding (LnC) RNAs in extracellular vesicles, are emerging as new prognostic tools.

Conference:

Presenting Author:

Authors: Manoharan J, Khizanishvili N, Krasser-Gercke N, Albers M, Mintziras I,

Keywords: Multiple endokrine neoplasia type 1, Extracellular vesicles, Non-functioning pancreatic neuroendocrine neoplasia, exosomal-LnC-RNA NEAT1, exosomal miRNA451a,

#3704 Impact of surgical approach on short- and long-term outcomes in gastroenteropancreatic neuroendocrine carcinomas

Introduction: Complete resection is the cornerstone of curative-intent treatment for gastroenteropancreatic neuroendocrine carcinomas (GEP-NECs) without distant metastases. However, there is a paucity of data on the impact of recent advancements in minimally invasive surgery (MIS), such as the utilization of laparoscopic and robotic approaches, on GEP-NEC patients’ outcomes.

Conference:

Presenting Author: Chen Q

Authors: Chen Q, Rhodin K, Li K, Kanu E, Zani S,

Keywords: Gastroenteropancreatic neuroendocrine carcinoma, Minimally Invasive Surgery, Open resection, Laparoscopic resection, Robotic resection, Outcome,

#3331 Outcomes of upfront treatment with mFOLFIRINOX regimen in G3 GEP-NENs: A monocentric retrospective experience

Introduction: To date outcomes of standard chemotherapy are not homogeneous in different subgroups of G3 GEP-NENs and remain unsatisfactory and poor; new therapeutic options are desirable in this setting.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Borghesani M

Authors: Borghesani M, Reni A, Zaninotto E, Fumagalli A, Benini L,

Keywords: net, mfolfirinox, chemotherapy, g3, minen,

#3328 Role of neoadjuvant PRRT in resectable/borderline resectable PanNETs: Clinical, pathological and genomic features

Introduction: The role of preoperative therapies to obtain cytoreduction, especially PRRT, is unclear.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Fumagalli A

Authors: Fumagalli A, Pellicciari M, Reni A, Borghesani M, Zaninotto E,

Keywords: net, prrt, neuroendocrine tumor, pancreas, genomic, neoadjuvant treatment,

#3167 Safety of Irinotecan-based chemotherapy as second-line treatment in extrapulmonary poorly differentiated neuroendocrine carcinomas (NECs)

Introduction: Owing to their low incidence, little evidence is available on the proper treatment of Neuroendocrine Carcinomas (NECs), a subgroup of tumors with scarce prognosis. Platinum plus Etoposide have been validated as first-line therapy since the 1991, while there is no consensus regarding further-lines treatment. Irinotecan (IRI)-based chemotherapy have shown promising results in second-line setting but data on safety are poor.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Bardasi C

Authors: Bardasi C, Spallanzani A, Luppi G, Bertolini F, Fontana A,

Keywords: neuroendocrine carcinoma, Irinotecan, safety, second-line treatment, chemotherapy, NEC, adverse events,